Research Article

In Vitro and *In Vivo* Survival and Colonic Adhesion of *Pediococcus acidilactici* MTCC5101 in Human Gut

Praveen P. Balgir, Baljinder Kaur, Tejinder Kaur, Natisha Daroch, and Gurpreet Kaur

Department of Biotechnology, Punjabi University, Punjab, Patiala 147 002, India

Correspondence should be addressed to Baljinder Kaur; baljinderbt@hotmail.com

Received 30 April 2013; Revised 13 August 2013; Accepted 14 August 2013

Academic Editor: Xiaoling Miao

Copyright © 2013 Praveen P. Balgir et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The present study aims to investigate the probiotic nature of *Pediococcus acidilactici* MTCC5101 by an *in vitro* assay of bacterial adherence to intestinal epithelial cells of human gastrointestinal (GI) tract using Caco-2 cell line. Further to assess the *in vivo* survival in the GI tract, oral feeding was carried out with the help of 10 healthy volunteers. The effect on wellness was assessed by studying blood biochemical parameters of the volunteers. The survival of the bacteria was assessed using PCR-based detection of *P. acidilactici* MTCC5101 in fecal samples. The probiotic nature of *P. acidilactici* MTCC 5101 was strengthened by its adherence to the intestinal epithelial Caco-2 cell line in the *in vitro* SEM observations. Oral feeding study for assessing the survival of bacteria in GI tract of volunteers showed the strain to be established in the GI tract which survived for about 2 weeks after feeding.

1. Introduction

Human intestinal microbiota is a metabolically active microbial environment that is relatively stable in the guts of healthy individuals [1]. The commensal intestinal flora of humans and animals includes the genera *Lactobacillus*, *Pediococcus*, and *Lactococcus* [2, 3]. Strains of these genera are frequently used on large scale as starter cultures in food industries because of their generally recognized as safe (GRAS) and probiotic status [4–6].

Probiotics are known to exert protective influence in the human intestine through various mechanisms and represent promising applications in prophylaxis and therapy. It has also been acknowledged by WHO that probiotic microorganisms when administered in adequate amounts confer a health benefit to the host [7]. Improvement of health status by probiotics can be explained by the fact that these bacteria reduce production of toxic substances, aid in production and absorption of vital nutrients, stimulate gastrointestinal activity as well as immunity, and reduce colonization of anaerobic pathogens by competitive exclusion [8, 9].

For all the health giving effects, the probiotic bacteria should also be capable of surviving while passage through the GI tract. It is essential for them to overcome highly acidic

environment of stomach, digestive enzymes, and bile salts of the small intestine, which thus become important selection criterion for probiotic strains. Apart from this, adherence of bacterial cells to intestinal epithelial cells and/or mucus is considered to be a desirable feature of probiotics, as it promotes enhanced gut residence time, pathogen exclusion, and interaction with host epithelial and immune cells [10, 11].

Pediococcus acidilactici MTCC5101 is an acid and bile tolerant probiotic strain that secretes a potent antibacterial bacteriocin designated as Pediocin CP2. Pediocin CP2 exhibits a wide range of antimicrobial activity against Gram-positive, Gram-negative bacteria as well as fungi [12]. Genes encoding production of Pediocin CP2 are localized to the *ped* operon present on the 8.9 kb plasmid pCP289 of *P. acidilactici* MTCC5101 [13–15]. These properties make this sp. of *Pediococcus* an attractive prophylactic and therapeutic agent against pathogenic bacteria in GI tract. However, the final confirmation of its probiotic nature can come only from human trials. It is these trials that provide evidence of the survival of the probiotic strain *in vivo* and provide the required basis for a credible claim.

The present study aims to investigate the probiotic nature of *P. acidilactici* MTCC5101 by an *in vitro* assay of bacterial adhesion to intestinal epithelial cells of human GI tract using

Caco-2 cell line. Further, to assess the *in vivo* survival in the GI tract, oral feeding was carried out with the help of 10 healthy volunteers. The effect on wellness was assessed by studying blood biochemical parameters of the volunteers.

2. Materials and Methods

2.1. Bacterial Strain Procurement and Maintenance. *Pediococcus acidilactici* MTCC5101, characterized in the laboratory of Department of Biotechnology, Punjabi University, Patiala [12], was used in the present study. It was revived and maintained at 37°C for 18–24 h under microaerophilic conditions in de Man, Rogosa, and Sharpe (MRS) broth [16].

2.2. In Vitro Adhesion Assay of *Pediococcus acidilactici* MTCC5101. The enterocyte-like Caco-2 cells were obtained from National Centre for Cell Science (NCCS), Pune. Cells were routinely grown in Dulbecco modified Eagle's minimal essential medium containing 25 mM glucose, 10% fetal bovine serum, and 1% antibiotic solution containing penicillin and streptomycin (Himedia) [15].

The adherence of pediococci to Caco-2 cells was examined as described previously by Bernet et al. [17] with a few modifications. For the adhesion assay, monolayers of Caco-2 cells were prepared on glass coverslips placed in six-well tissue culture plates seeded at a concentration of 10^6 cells/mL. Experiments were carried out at 37°C in a 5% CO₂ atmosphere. The culture medium was changed every alternate day and monolayers at late postconfluence stage (after 15 days) were used for adhesion assay. To begin with the assay, monolayers were washed twice with phosphate-buffered saline (PBS, pH 7.2). 1 mL bacterial culture containing one million CFU/mL suspended in PBS was added to the monolayers on glass coverslips placed in tissue culture plates containing DMEM without antibiotic solution. The plates were incubated for 1 h in 5% CO₂ at 37°C. After 1 h, the monolayers were washed five times with sterile PBS and fixed for SEM observations. The adhesion assay was repeated thrice.

2.3. Scanning Electron Microscopy (SEM). For SEM analysis, Caco-2 cells cocultured with bacterial cells were fixed for 1 h with 2.5% glutaraldehyde in 0.1 M phosphate buffer (PB, pH 7.4) at room temperature. The cells were washed twice with PB and postfixed for 30 min with 2% osmium tetroxide in PB. After fixation, cells were again washed thrice with PB and then dehydrated in a graded series (30, 50, 70, 80, 90, and 100%) of ethanol [17]. Instead of critical point dryer, cells were treated with 100% hexamethyldisilazane for 10 min and coated with gold [18]. The specimens were examined with a JEOL JSM-6610LV scanning electron microscope at Indian Institute of Technology, Ropar, Punjab, India. A number of bacterial cells adhered onto Caco-2 cells were counted on various microscopic fields per coverslip while performing SEM. The values were represented as average number of bacterial cells adhered per 100 Caco-2 cells.

2.4. In Vivo Study Design. The study was approved by the Institutional Clinical Ethics Committee vide clearance no.

ICEC/3/2011. Experiments were strictly performed according to the guidelines of Indian Council of Medical Research for conducting research on human trials. Ten healthy volunteers were selected after taking their informed consent. It was a controlled study consisting of parallel 6 weeks trials, with 4 weeks of intervention and 2 weeks wash-out period.

2.4.1. Preparation of Probiotic Buttermilk. The overnight grown *P. acidilactici* MTCC5101 cells were harvested by centrifugation (6000 rpm, 10 min) and resuspended slowly in PBS (pH 8.0). Cells at a concentration of 10^8 – 10^{10} cells/mL were added to fresh buttermilk as medium for oral feeding study (Verka Co. Ltd., Patiala, India). Cell counts were taken on a haemocytometer [19] and after thorough microbiological examination, cells at an average dosage level of 10^8 – 10^{10} cells/mL/day were fed to 10 healthy subjects in 1 mL buttermilk base, administered once a day for 4 weeks continuously [20]. Equivalent amount of buttermilk without *P. acidilactici* MTCC5101 was fed to a group of 3 control volunteers which served as negative controls. The subjects were asked to abstain from taking other fermented milk products and supplements with probiotics during the trial period. They were explained how to collect, store, and deliver the fecal samples. Participants were asked about changes in their wellbeing and/or had taken any kind of medication during study period.

2.4.2. Collection and Analysis of Fecal Samples. The fecal swab samples were collected using ear buds in 2 mL of sterile normal saline (0.85% NaCl) after feeding trials of 5, 10, 20, and 30 days [38]. The fecal suspension was cultured in MRS broth for bacterial enumeration for 18 h at 37°C. Cell pellets were harvested by centrifugation and were stored at –20°C for plasmid DNA isolation.

2.4.3. Molecular Identification of *P. acidilactici* MTCC5101 in Fecal Samples. A metagenomic approach was followed for the isolation of plasmid DNA from fecal samples [39]. Isolated DNA was stored at –20°C until further use and its quality, quantity, and purity were determined using agarose gel electrophoresis and absorbance measurements on spectrophotometer (UV mini-1240, UV-Vis spectrophotometer, Shimadzu Corporation). PCR was performed in PROGENE (Techne) using forward primer 5'-CTGCGTTGATAGGCCAGGT-3' and reverse primer 5'-ACCTTGATGTCCACCAGTAGC-3' which are specific for 323 bp fragment of *pedA* gene located on the cryptic plasmid pCP289 of *P. acidilactici* MTCC5101 [13]. The amplification program consisted of 1 cycle of 94°C for 3 min and 30 cycles of amplification (94°C for 1 min, 63°C for 1 min, and 72°C for 1 min).

2.4.4. Bacteriocin Activity Assay. Well diffusion assay was performed as per standard methodology of Sarkar and Banerjee [40]. MRS hard agar (1% w/v) was overlaid with MRS soft agar (0.75% w/v) preseeded with approximately one million cells of indicator *Enterococcus faecalis*. Wells were filled with heat inactivated supernatant of MRS grown fecal

TABLE 1: Viable cell counts of *P. acidilactici* MTCC5101 in buttermilk base.

Food base	Bacterial count ^a (cells/mL)			
	Week 1	Week 2	Week 3	Week 4
<i>P. acidilactici</i> MTCC5101/mL of buttermilk base	9.9×10^8	1.01×10^9	1×10^{10}	1.02×10^{10}

^aValues are expressed as cells/mL.

samples pertaining to the 30th day of intervention and plates were incubated at 37°C for 24 h.

2.5. Determination of Wellness Parameters. To check the effect of the probiotic on the wellness of test subjects, blood samples were drawn 2 weeks before and 2 weeks after the intervention. Wellness parameters such as total white blood cells (WBC) and red blood cells (RBC) counts, Hb (Haemoglobin), bleeding, and clotting time were recorded.

2.6. Statistics. Statistical analysis of data was performed using the Daniel's XL Toolbox, version 5.09. For the cell counts and hematological analysis, significant differences in the observed values were tested using one-way analysis of variance (ANOVA). When significant differences were found, multiple comparison/post hoc testing based on Bonferroni-Holm was carried out. Differences were considered statistically significant when $P < 0.05$.

3. Results

3.1. Adhesion of *P. acidilactici* MTCC5101 to Caco-2 Cells. Figures 1(a) and 1(b) represent SEM micrographs of untreated Caco-2 cells and *P. acidilactici* MTCC5101 with their typical tetrad arrangement. After examining the SEM images of cocultured *P. acidilactici* MTCC5101 with Caco-2 cells, it is clearly illustrated that the selected probiotic has a very high tendency to adhere to intestinal epithelium or Caco-2 cells at the mucosal surface. Adhesion of selected probiotic strain onto monolayers of Caco-2 cells was evaluated on different microscopic fields per coverslip and at an average 152 ± 33 cells adhered per 100 Caco-2 cells. A biofilm of adherent bacteria constituted of pediococci was observed. The bacteria were also found to adhere to each other (Figures 1(c) and 1(d)).

3.2. Total LAB Count in Fecal Samples. In Table 1 the total cell counts of *P. acidilactici* MTCC5101 in buttermilk base are recorded. All the subjects have received oral doses of 10^8 – 10^{10} cells/mL/day of *P. acidilactici* in buttermilk base. The fecal swab samples cultured in MRS medium showed growth of mixed LAB with cell counts of 9.27 ± 1.01 cells/mL at the baseline (day 0) and 9.31 ± 0.98 cells/mL after 4 weeks of intervention. Similarly, fecal swab samples from control group showed cell counts of 10.17 ± 1.06 cells/mL at the baseline and 9.76 ± 0.33 cells/mL after 4 weeks (Table 2).

3.2.1. Molecular Identification of *P. acidilactici* MTCC5101 in Fecal Samples. Results of the PCR analysis coincide with

TABLE 2: Total LAB counts enumerated in fecal samples.

Interval (days)	Bacterial counts (cells/mL) ^a	
	VC ($n = 3$)	VS ($n = 10$)
At baseline (day 0)	10.17 ± 1.06	9.27 ± 1.01
After intervention (day 30)	9.76 ± 0.33	9.31 ± 0.98

^aValues are expressed as mean $\pm$ SD of $\log^{10}$ values.

VC: volunteer controls.

VS: volunteer subjects.

(n): no. of individuals.

TABLE 3: Haematological analysis of healthy human subjects.

Haematological tests	Interval	Response in volunteers ^a	
		VC ($n = 3$)	VS ($n = 10$)
WBC counts (per mm ³ of blood)	Before	3.73 ± 0.02	3.71 ± 0.05
	After	3.71 ± 0.03	3.70 ± 0.04
RBC counts (per mm ³ of blood)	Before	6.63 ± 0.02	6.56 ± 0.06
	After	6.62 ± 0.02	6.66 ± 0.03
Hb (gm/dL)	Before	0.98 ± 0.02	0.95 ± 0.03
	After	0.98 ± 0.05	3.15 ± 4.4
Bleeding time (sec)	Before	2.09 ± 0.03	2.04 ± 0.11
	After	2.10 ± 0.03	2.04 ± 0.13
Clotting time (sec)	Before	2.35 ± 0.08	2.34 ± 0.07
	After	2.34 ± 0.07	2.35 ± 0.06

^aValues are expressed as mean $\pm$ SD of $\log^{10}$ values.

VC: volunteer controls.

VS: volunteer subjects.

(n): no. of individuals.

count data that indicates detectable levels of *P. acidilactici* MTCC5101 in all the volunteers after a 4-week intervention. Figures 2(a) and 2(b) depict agarose gel analysis of 323 bp fragment of partial *pedA* gene amplified from isolated whole LAB plasmids of 5th and 10th day's fecal samples. Intensity of the PCR amplicon is lesser in the 5th day's samples which show that the establishment of the probiotic strain requires a little longer time to persist and colonize in the human gut. The fragment of the expected size was obtained in nearly all 10th day's samples and the bands in agarose gels were more prominent as compared to 5th day which confirms that the pediococci have started gut colonization. A similar pattern is observed in the 20th and 30th day's fecal samples on 2% agarose (Figures 2(c) and 2(d)). The band intensity was more prominent as compared to 5th and 10th day samples which indicate that the strain has colonized in the GI tract of volunteers, hence proving that colonization progresses in a time-dependent manner.

3.2.2. Bacteriocin Activity Assay. To check for pediocin CP2 profile in the mixed fecal cell cultures of 30th day, standard well diffusion assay was carried out using *E. faecalis* as the indicator strain. After 24 h, definite zone of inhibition was seen in the plates that also confirms our previous findings on successful establishment of *P. acidilactici* MTCC5101 in GI tract of volunteers (Figure 3).

FIGURE 1: SEM micrographs of (a) untreated Caco-2 cells (magnification level 4,000x) (b) *P. acidilactici* MTCC 5101 (magnification level 9,000x), and (c) and (d) adherent *P. acidilactici* MTCC 5101 on Caco-2 cells (magnification level 2,000x and 6,500x).

TABLE 4: Adhesion studies based on Probiotics.

Organism(s)	Cells/cell line(s)	Adhesion index*	Reference
<i>Bifidobacterium breve</i> (4, 5, 25) <i>B. longum</i> (4, 16, 18, 22) <i>B. bifidum</i> (7, 8) <i>B. infantis</i> (1)	Caco-2 HT29-MTX	<i>B. breve</i> (4): 205 ± 18 <i>B. longum</i> (16): 72 ± 13 <i>B. bifidum</i> (8): 35 ± 6 <i>B. infantis</i> (1): 161 ± 14	[17]
<i>Lactobacillus rhamnosus</i> GG <i>L. casei</i> strain Shirota <i>L. johnsonii</i> La1 <i>L. rhamnosus</i> LC 705 <i>B. lactis</i> Bb12	Mucus from feces	<i>L. rhamnosus</i> GG: 28.8% <i>L. johnsonii</i> La1: 27.3% <i>B. lactis</i> Bb12: 10.0% <i>L. casei</i> strain Shirota: 4.0% <i>L. rhamnosus</i> Lc705: 1.3%	[21]
<i>L. rhamnosus</i> GG <i>B. animalis</i> subsp. <i>lactis</i> Bb12 <i>B. animalis</i> IATA-A2 <i>B. bifidum</i> IATA-ES2	Caco-2 HT29-MTX	HT29-MTX: 0.5–2.3% Caco-2/HT29-MTX: 0.6–3.2%	[22]
<i>L. plantarum</i> (9, 72, 75, 77, 90, 91) <i>L. delbrueckii</i> subsp. <i>bulgaricus</i> CH4 <i>L. plantarum</i> CSCC5276	HT-29 Caco-2	<i>L. plantarum</i> Lp91: 12.8 ± 1.56	[23]
163 <i>Lactobacillaceae</i> sp.	HT-29 HT-29 MTX	HT-29 Pediococci: 12.51% ± 1.4% Lactobacilli: 4.8% ± 61.6% HT-29 MTX Pediococci: 13.5% ± 62.0% Lactobacilli: 10.3% ± 62.4%	[24]
<i>P. acidilactici</i> MTCC 5101	Caco-2	<i>P. acidilactici</i> : 152 ± 33	Present study

* Adhesion is indexed as % adhesion or mean ± SD of the number of bacterial cells adhered per 100 cells of cell line used.

FIGURE 2: 2% agarose gel showing 323 bp DNA fragment amplified using plasmids from fecal samples (a) M: marker pUC 19/Msp Digest, C(+): positive control, Lane 1–10: 5th day samples, C(–): negative control. (b) M: marker pUC 19/Msp digest, C(+): positive control, lane 1–10: 10th day's samples, C(–): Negative control. (c) M: Marker pUC 19/Msp Digest, C(+): Positive control, Lane 1–10: 20th day's samples, C(–): negative control. (d) M: marker pUC 19/Msp Digest, C(+): positive control, lane 1–10: 30th day's samples, C(–): negative control.

FIGURE 3: Well diffusion assay of cultured fecal samples of 30th day's against *E. faecalis*. C: *P. acidilactici* MTCC 5101; C1–C3: Fecal swab samples of volunteer controls; 1–10: Fecal swab samples of volunteer subjects.

3.3. Wellness Parameters Performed. Routine blood tests were performed to estimate the effect of probiotics on wellness parameters of volunteers. The tests include WBC and RBC counts, levels of Hb in blood, bleeding time, and clotting time (Table 3). Haematological survey was carried out before as well as after feeding trial to estimate the effect of probiotics on some of the wellness parameters of test subjects. Results indicated a small yet insignificant increase in the values of RBC counts and Hb levels of subjects. The findings confirm the safe oral consumption and health improvement capacity of probiotic strain.

4. Discussion

Bacterial adhesion to epithelial cells in gut is initially based on nonspecific physical interactions between the two surfaces

[41, 42]. After primary attachment to epithelial surface, secondary interactions between bacterial adhesins and complementary epithelial receptors play a key role in adhesion of bacterial cells to intestinal mucin and enterocytes [22, 43–47]. Since there is difficulty in studying bacterial adhesion *in vivo*, intestinal cell lines are widely used as *in vitro* models for assessment [48]. We have used a well-characterized cultured colon carcinoma Caco-2 cell line displaying typical features of enterocytic differentiation in the form of villi to study adhesion of *P. acidilactici* MTCC5101. A strong adherence of probiotic strains to intestinal epithelial cells has been reported previously in a number of studies (Table 4). In a recent study by Jensen et al. [49], it has been reported that the adhesion capacity of probiotics varies from species to species as a variation from 1% to 25% has been observed in case of 18 known probiotic lactobacilli and pediococci.

TABLE 5: Studies of oral dosage levels of probiotics in healthy volunteers and patients.

Organism(s)	Subjects	Dose levels (CFU/mL/day)	Response/outcomes	Reference
<i>Lactobacillus paracasei</i> subsp. <i>paracasei</i> (CRL-431) <i>L. acidophilus</i>	Children and adults with diarrhea	10^7 - 10^8	Three 15 day trial periods; reduction in incidence of intestinal disorders	[25]
<i>Lactobacillus</i> GG	Healthy volunteers	10^8 - 10^{10}	1-week trial; effective gut colonization	[26]
<i>Bifidobacterium lactis</i> BB-12 <i>Lactobacillus</i> GG	Children with atopic eczema	10^8 - 10^9	2-month trial; controlled allergic reactions	[27]
<i>B. longum</i> SBT2928	Healthy volunteers	10^{11}	40-day trial; survival in the gut	[28]
<i>Lactobacillus</i> GG	Children with acute infectious diarrhea	10^9	Prophylactic; reduction in duration of diarrhea	[29]
<i>L. casei</i> subsp. <i>rhamnosus</i> Lcr35	Healthy volunteers	10^8 - 10^{12}	1-week study; successful colonization of gut	[30]
<i>L. reuteri</i> ATCC 55730	Healthy volunteers	10^8	28-day trial; gut colonization; immune modulation	[31]
<i>B. animalis</i> subsp. <i>lactis</i> BB-12 <i>Streptococcus thermophilus</i>	Children with rotavirus diarrhea	10^8	Reduction in incidence of acute diarrhea and rotavirus shedding	[32]
<i>B. lactis</i> strain BB12	Healthy breastfed infants	10^6	Prophylactic against acute diarrhea	[33]
<i>B. animalis</i> subsp. <i>lactis</i> BB-12 <i>L. reuteri</i> ATCC 55730	Children with acute diarrhea	10^7	12-week trial; fewer and shorter episodes of diarrhea	[34]
<i>L. delbrueckii</i> subsp. <i>bulgaricus</i> <i>S. thermophilus</i>	Healthy volunteers	10^7 - 10^9 (<i>L. delbrueckii</i>) 10^8 - 10^{10} (<i>S. thermophilus</i>)	12-day trial; effective gut colonization	[35]
<i>B. animalis</i> subsp. <i>lactis</i> BB-12 <i>L. paracasei</i> subsp. <i>paracasei</i> CRL-431	Healthy volunteers	10^8 - 10^{11}	7-week study; fecal recovery increases with increase in dose	[36]
<i>L. reuteri</i> DSM 17938 <i>L. rhamnosus</i> GG	Healthy volunteers	10^9	3-week trial; increase in fecal recovery of viable lactobacilli	[37]
<i>Pediococcus acidilactici</i> MTCC 5101	Healthy human volunteers	10^8 - 10^{10}	4-week trial; colonization and fecal recovery increases with time	Present study

The current study provides clear evidence that *P. acidilactici* MTCC5101 adheres strongly to villi of Caco-2 cells. These results further strengthened the claim of this strain for selection as a probiotics for human use.

Oral consumption of probiotics has been advocated with prophylactic and curative properties that have been observed in case of intestinal disorders such as antibiotic-induced diarrheal disease, viral and bacterial diarrhea, lactose intolerance, and inflammatory bowel diseases [27, 29, 34, 50–55]. Recently, there has been accumulation of evidence from rigorous clinical studies on well-characterized probiotics having real health-promoting properties [56, 57].

Although minimum effective dose is not known exactly, usually an oral dose of 10^6 CFU/day or more than this has been followed in most studies (Table 5). Previous clinical and colonization studies prove successful intestinal colonization of probiotic bacteria and prevention of diseased condition. A comparative analysis of such *in vivo* clinical studies demonstrates that the persistence time of probiotic bacteria in gut varies from strain to strain (Table 5). The relative strain-specific persistence *in vivo* correlates accurately and significantly with *in vitro* outcomes as evident from a recent study on *Lactobacillus plantarum* [58]. Studies on probiotic *Lactobacillus casei* strain DN-114 001 and *L. casei* strain

Shirota have proven the capacity of these strains to survive and colonize human gut [59, 60]. Persistence of probiotic strains in GI tract is also demonstrated by their bile and acid resistance properties, as shown in earlier study carried out on the present strain [12, 61–64].

Survival in the GI tract depends on both the strain and the food matrix involved [65]. Fecal recovery of several probiotic strains has been demonstrated in different food matrices, including fermented milk and yoghurt [66, 67], fruit drinks [68], supplements [36, 69], and infant formula [65]. The survival of probiotics in human GI tract should lead to shedding of live cells in fecal samples which can be detected using quantitative methods like PCR [37, 70]. In the present parallel, controlled human intervention study, *in vivo* persistence and colonization of *P. acidilactici* MTCC5101 in GI tract provides a clear evidence for intimate interactions between the selected probiotic bacteria and intestinal mucosal surface. These interactions allow probiotic strain to persist in gut for a considerable time period, regardless of the dietary and physiological differences among individuals selected in the study. Furthermore, results indicate that buttermilk is a suitable carrier medium for *P. acidilactici* MTCC5101 strengthening the use of buttermilk as a probiotic product.

Abnormal blood biochemical parameters are an indicator of a number of clinical disorders. Oral consumption of probiotics has not been linked to any adverse subclinical effects on blood biochemistry so far [71, this study]. Probiotics have been reported to enhance absorption of essential vitamins and minerals from the diet into the body [72, 73]. The enhanced absorption of vitamins and minerals has led to improved haematological environment and gut health. A slight increase in RBC counts and Hb levels of volunteer subjects after oral feeding with probiotics strain was observed. Both *in vitro* models and *in vivo* studies have suggested the successful establishment of *P. acidilactici* MTCC5101 in human gut that is being proposed herein with the possibility of providing beneficial health effects to the host.

5. Conclusions

In conclusion, *P. acidilactici* MTCC5101 can survive passage through the human GI tract when administered orally in a buttermilk food base. Overall, results indicate that *P. acidilactici* MTCC5101 is a safe and potent probiotic strain with strong adhesive and health-improving characteristics. The findings suggest an opportunity for successful use of *P. acidilactici* MTCC5101 in functional food applications in future.

Conflict of Interests

The authors declare that they have no conflict of interests.

Acknowledgment

This work has been supported by Department of Science and Technology, Government of India (Major Research Project no. SR/SO/HS-38/2009).

References

- [1] A. S. Neish, "Microbes in gastrointestinal health and disease," *Gastroenterology*, vol. 136, no. 1, pp. 65–80, 2009.
- [2] E. E. Vaughan, H. G. H. J. Heilig, K. Ben-Amor, and W. M. de Vos, "Diversity, vitality and activities of intestinal lactic acid bacteria and bifidobacteria assessed by molecular approaches," *FEMS Microbiology Reviews*, vol. 29, no. 3, pp. 477–490, 2005.
- [3] E. G. Zoetendal, E. E. Vaughan, and W. M. de Vos, "A microbial world within us," *Molecular Microbiology*, vol. 59, no. 6, pp. 1639–1650, 2006.
- [4] S. Salminen, A. von Wright, L. Morelli et al., "Demonstration of safety of probiotics—a review," *International Journal of Food Microbiology*, vol. 44, no. 1-2, pp. 93–106, 1998.
- [5] F. J. Carr, D. Chill, and N. Maida, "The lactic acid bacteria: a literature survey," *Critical Reviews in Microbiology*, vol. 28, no. 4, pp. 281–370, 2002.
- [6] S. P. Borriello, W. P. Hammes, W. Holzapfel et al., "Safety of probiotics that contain *Lactobacilli* or bifidobacteria," *Clinical Infectious Diseases*, vol. 36, no. 6, pp. 775–780, 2003.
- [7] Food and Agriculture Organization of the United Nations-World Health Organization Working Group, "Guidelines for the evaluation of probiotics in foods," Report of a Joint FAO/WHO Working Group on Drafting Guidelines for the Evaluation of Probiotics in Food, World Health Organization, Geneva, Switzerland, 2002.
- [8] J. Ezendam and H. van Loveren, "Probiotics: immunomodulation and evaluation of safety and efficacy," *Nutrition Reviews*, vol. 64, no. 1, pp. 1–14, 2006.
- [9] S. Lebeer, J. Vanderleyden, and S. C. J. de Keersmaecker, "Host interactions of probiotic bacterial surface molecules: comparison with commensals and pathogens," *Nature Reviews Microbiology*, vol. 8, no. 3, pp. 171–184, 2010.
- [10] M. C. Collado, E. Isolauri, S. Salminen, and Y. Sanz, "The impact of probiotic on gut health," *Current Drug Metabolism*, vol. 10, no. 1, pp. 68–78, 2009.
- [11] S. Lebeer, J. Vanderleyden, and S. C. J. de Keersmaecker, "Genes and molecules of *Lactobacilli* supporting probiotic action," *Microbiology and Molecular Biology Reviews*, vol. 72, no. 4, pp. 728–764, 2008.
- [12] B. Kaur and P. P. Balgir, "Purification, characterization and antimicrobial range of bacteriocin obtained from an isolate of *Pediococcus* spp.," *Journal of Punjab Academy of Sciences*, vol. 1, no. 2, pp. 139–144, 2004.
- [13] B. Kaur and P. P. Balgir, "Pediocin CP2 gene localization to plasmid pCP289 of *Pediococcus acidilactici* MTCC 5101," *Internet Journal of Microbiology*, vol. 3, no. 2, 2007.
- [14] B. Kaur and P. P. Balgir, "Biopreservative potential of a broad-range pediocin CP2 obtained from *Pediococcus acidilactici* MTCC 5101," *Asian Journal of Microbiology, Biotechnology and Environmental Sciences*, vol. 10, no. 2, pp. 439–444, 2008.
- [15] B. Kumar, P. P. Balgir, B. Kaur, B. Mittu, and A. Chauhan, "In vitro cytotoxicity of native and rec-pediocin CP2 against cancer cell lines: a comparative study," *Pharmaceutical Analytical Acta*, vol. 1, no. 6, article 316, 2012.
- [16] J. C. de Man, M. Rogosa, and M. E. Sharpe, "A medium for the cultivation of *Lactobacilli*," *Journal of Applied Bacteriology*, vol. 23, no. 1, pp. 130–135, 1960.
- [17] M.-F. Bernet, D. Brassart, J.-R. Neeser, and A. L. Servin, "Adhesion of human bifidobacterial strains to cultured human intestinal epithelial cells and inhibition of enteropathogen-cell interactions," *Applied and Environmental Microbiology*, vol. 59, no. 12, pp. 4121–4128, 1993.
- [18] F. Braet, R. de Zanger, and E. Wisse, "Drying cells for SEM, AFM and TEM by hexamethyldisilazane: a study on hepatic endothelial cells," *Journal of Microscopy*, vol. 186, no. 1, pp. 84–87, 1997.
- [19] J. Berkson, T. B. Magath, and M. Hurn, "The error of estimate of the blood cell count as made with the hemocytometer," *The American Journal of Physiology*, vol. 128, pp. 309–323, 1939.
- [20] M. Elli, M. L. Callegari, S. Ferrari et al., "Survival of yogurt bacteria in the human gut," *Applied and Environmental Microbiology*, vol. 72, no. 7, pp. 5113–5117, 2006.
- [21] A. C. Ouwehand, T. Kurvinen, and P. Rissanen, "Use of a probiotic *Bifidobacterium* in a dry food matrix, an *in vivo* study," *International Journal of Food Microbiology*, vol. 95, no. 1, pp. 103–106, 2004.
- [22] J. M. Laparra and Y. Sanz, "Comparison of *in vitro* models to study bacterial adhesion to the intestinal epithelium," *Letters in Applied Microbiology*, vol. 49, no. 6, pp. 695–701, 2009.
- [23] R. K. Duany, M. A. Bhausheh, V. K. Batish, and S. Grover, "Anti-inflammatory and immunomodulatory efficacy of indigenous probiotic *Lactobacillus plantarum* Lp91 in colitis mouse model," *Molecular Biology Reports*, vol. 39, no. 4, pp. 4765–4775, 2012.

- [24] W. Turpin, C. Humblot, M. Noordine, M. Thomas, and J. Guyot, "Lactobacillaceae and cell adhesion: genomic and functional screening," *PLoS ONE*, vol. 7, no. 5, Article ID e38034, 2012.
- [25] S. Gonzalez, G. Albarracin, M. L. de Ruiz Pesce et al., "Prevention of infantile diarrhoea by fermented milk," *Microbiologie, Aliments, Nutrition*, vol. 8, pp. 349–354, 1990.
- [26] M. Saxelin, M. Ahokas, and S. Salminen, "Dose response on the faecal colonisation of *Lactobacillus* strain GG administered in two different formulations," *Microbial Ecology Health Diseases*, vol. 6, no. 3, pp. 119–122, 1993.
- [27] E. Isolauri, T. Arvola, Y. Sutas, E. Moilanen, and S. Salminen, "Probiotics in the management of atopic eczema," *Clinical and Experimental Allergy*, vol. 30, no. 11, pp. 1604–1610, 2000.
- [28] S. Fujiwara, Y. Seto, A. Kimura, and H. Hashiba, "Intestinal transit of an orally administered streptomycin-rifampicin-resistant variant of *Bifidobacterium longum* SBT2928: its long-term survival and effect on the intestinal microflora and metabolism," *Journal of Applied Microbiology*, vol. 90, no. 1, pp. 43–52, 2001.
- [29] H. Szajewska and J. Z. Mrukowicz, "Probiotics in the treatment and prevention of acute infectious diarrhea in infants and children: a systematic review of published randomized, double-blind, placebo-controlled trials," *Journal of Pediatric Gastroenterology and Nutrition*, vol. 33, no. 4, pp. S17–S25, 2001.
- [30] C. de Champs, N. Maroncle, D. Balestrino, C. Rich, and C. Forestier, "Persistence of colonization of intestinal mucosa by a probiotic strain, *Lactobacillus casei* subsp. *rhannosus* Lcr35, after oral consumption," *Journal of Clinical Microbiology*, vol. 41, no. 3, pp. 1270–1273, 2003.
- [31] N. Valeur, P. Engel, N. Carbajal, E. Connolly, and K. Ladefoged, "Colonization and immunomodulation by *Lactobacillus reuteri* ATCC 55730 in the human gastrointestinal tract," *Applied and Environmental Microbiology*, vol. 70, no. 2, pp. 1176–1181, 2004.
- [32] J. M. Saavedra, N. A. Bauman, I. Oung, J. A. Perman, and R. H. Yolken, "Feeding of *Bifidobacterium bifidum* and *Streptococcus thermophilus* to infants in hospital for prevention of diarrhoea and shedding of rotavirus," *The Lancet*, vol. 344, no. 8929, pp. 1046–1049, 1994.
- [33] J. Chouraqui, L. van Egroo, and M. Fichot, "Acidified milk formula supplemented with *Bifidobacterium lactis*: impact on infant diarrhea in residential care settings," *Journal of Pediatric Gastroenterology and Nutrition*, vol. 38, no. 3, pp. 288–292, 2004.
- [34] Z. Weizman, G. Asli, and A. Alsheikh, "Effect of a probiotic infant formula on infections in child care centers: comparison of two probiotic agents," *Pediatrics*, vol. 115, no. 1, pp. 5–9, 2005.
- [35] D. D. G. Mater, L. Bretigny, O. Firmesse et al., "*Streptococcus thermophilus* and *Lactobacillus delbrueckii* subsp. *bulgaricus* survive gastrointestinal transit of healthy volunteers consuming yogurt," *FEMS Microbiology Letters*, vol. 250, no. 2, pp. 185–187, 2005.
- [36] C. N. Larsen, S. Nielsen, P. Kæstel et al., "Dose-response study of probiotic bacteria *Bifidobacterium animalis* subsp. *lactis* BB-12 and *Lactobacillus paracasei* subsp. *paracasei* CRL-341 in healthy young adults," *European Journal of Clinical Nutrition*, vol. 60, no. 11, pp. 1284–1293, 2006.
- [37] Y. E. M. Dommels, R. A. Kemperman, Y. E. M. P. Zebregs et al., "Survival of *Lactobacillus reuteri* DSM 17938 and *Lactobacillus rhamnosus* GG in the human gastrointestinal tract with daily consumption of a low-fat probiotic spread," *Applied and Environmental Microbiology*, vol. 75, no. 19, pp. 6198–6204, 2009.
- [38] J. Gossling and J. M. Slack, "Predominant gram-positive bacteria in human feces: numbers, variety, and persistence," *Infection and Immunity*, vol. 9, no. 4, pp. 719–729, 1974.
- [39] S. Atashpaz, S. Khani, A. Barzegari et al., "A robust universal method for extraction of genomic DNA from bacterial species," *Microbiology*, vol. 79, no. 4, pp. 538–542, 2010.
- [40] P. K. Sarkar and S. Banerjee, "Antibacterial activity of lactic acid bacterial isolates obtained from natural habitats," *Journal of Food Science and Technology*, vol. 33, no. 3, pp. 231–233, 1996.
- [41] R. Oliveira, "Understanding adhesion: a means for preventing fouling," *Experimental Thermal and Fluid Science*, vol. 14, no. 4, pp. 316–322, 1997.
- [42] M. Hermansson, "The DLVO theory in microbial adhesion," *Colloids and Surfaces B*, vol. 14, no. 1–4, pp. 105–119, 1999.
- [43] E. H. Beachey, "Bacterial adherence: adhesin-receptor interactions mediating the attachment of bacteria to mucosal surfaces," *Journal of Infectious Diseases*, vol. 143, no. 3, pp. 325–345, 1981.
- [44] H. M. Dalton and P. E. March, "Molecular genetics of bacterial attachment and biofouling," *Current Opinion in Biotechnology*, vol. 9, no. 3, pp. 252–255, 1998.
- [45] S. D. Knight, J. Berglund, and D. Choudhury, "Bacterial adhesins: structural studies reveal chaperone function and pilus biogenesis," *Current Opinion in Chemical Biology*, vol. 4, no. 6, pp. 653–660, 2000.
- [46] K. Otto, H. Elwing, and M. Hermansson, "The role of type 1 fimbriae in adhesion of *Escherichia coli* to hydrophilic and hydrophobic surfaces," *Colloids and Surfaces B*, vol. 15, no. 1, pp. 99–111, 1999.
- [47] V. K. Viswanathan, A. Koutsouris, S. Lukic et al., "Comparative analysis of EspF from enteropathogenic and enterohemorrhagic *Escherichia coli* in alteration of epithelial barrier function," *Infection and Immunity*, vol. 72, no. 6, pp. 3218–3227, 2004.
- [48] E. M. Lehto and S. Salminen, "Adhesion of two *Lactobacillus* strains, one *Lactococcus* and one *Propionibacterium* strain to cultured human intestinal Caco-2 cell line," *Bioscience and Microflora*, vol. 16, no. 1, pp. 13–17, 1997.
- [49] H. Jensen, S. Grimmer, K. Naterstad, and L. Axelsson, "In vitro testing of commercial and potential probiotic lactic acid bacteria," *International Journal of Food Microbiology*, vol. 153, no. 1–2, pp. 216–222, 2012.
- [50] S. N. Gonzalez, R. Cardozo, M. C. Apella, and G. Oliver, "Biotherapeutic role of fermented milk," *Biotherapy*, vol. 8, no. 2, pp. 129–134, 1994.
- [51] E. J. Schiffrin, F. Rochat, H. Link-Amster, J. M. Aeschlimann, and A. Donnet-Hughes, "Immunomodulation of human blood cells following the ingestion of lactic acid bacteria," *Journal of Dairy Science*, vol. 78, no. 3, pp. 491–497, 1995.
- [52] Y. Fukushima, Y. Kawata, H. Hara, A. Terada, and T. Mitsuoka, "Effect of a probiotic formula on intestinal immunoglobulin A production in healthy children," *International Journal of Food Microbiology*, vol. 42, no. 1–2, pp. 39–44, 1998.
- [53] D. Gaon, C. Garmendia, N. O. Murrielo et al., "Effect of *Lactobacillus* strains (*L. casei* and *L. acidophilus* strains cerela) on bacterial overgrowth-related chronic diarrhea," *Medicina*, vol. 62, no. 2, pp. 159–163, 2002.
- [54] S. Blum and E. J. Schiffrin, "Intestinal microflora and homeostasis of the mucosal immune response: implications for probiotic bacteria?" *Current Issues in Intestinal Microbiology*, vol. 4, no. 2, pp. 53–60, 2003.
- [55] A. L. Hart, K. Lammers, P. Brigidi et al., "Modulation of human dendritic cell phenotype and function by probiotic bacteria," *Gut*, vol. 53, no. 11, pp. 1602–1609, 2004.
- [56] M. de Vrese, A. Stegelmann, B. Richter, S. Fenselau, C. Laue, and J. Schrezenmeier, "Probiotics—compensation for lactase

- insufficiency," *The American Journal of Clinical Nutrition*, vol. 73, no. 2, pp. 421S–429S, 2001.
- [57] S. Messaoudi, G. Kergourlay, A. Rossero et al., "Identification of *Lactobacilli* residing in chicken ceca with antagonism against *Campylobacter*," *International Microbiology*, vol. 14, no. 2, pp. 103–110, 2011.
- [58] H. van Bokhorst-van de Veen, I. van Swam, M. Wels, P. A. Bron, and M. Kleerebezem, "Congruent strain specific intestinal persistence of *Lactobacillus plantarum* in an intestine-mimicking *in vitro* system and in human volunteers," *PLoS ONE*, vol. 7, no. 9, Article ID e44588, 2012.
- [59] R. Oozeer, A. Leplingard, D. D. G. Mater et al., "Survival of *Lactobacillus casei* in the human digestive tract after consumption of fermented milk," *Applied and Environmental Microbiology*, vol. 72, no. 8, pp. 5615–5617, 2006.
- [60] K. M. Tuohy, M. Pinart-Gilberga, M. Jones, L. Hoyles, A. L. McCartney, and G. R. Gibson, "Survivability of a probiotic *Lactobacillus casei* in the gastrointestinal tract of healthy human volunteers and its impact on the faecal microflora," *Journal of Applied Microbiology*, vol. 102, no. 4, pp. 1026–1032, 2007.
- [61] M. Mirlohi, S. Soleimanian-Zad, S. Dokhani, M. Sheikh-Zeinodin, and A. Abghary, "Investigation of acid and bile tolerance of native *Lactobacilli* isolated from fecal samples and commercial probiotics by growth and survival studies," *Iranian Journal of Biotechnology*, vol. 7, no. 4, pp. 233–240, 2009.
- [62] E. Both, E. Gyorgy, C. Z. Kibedi-szabo et al., "Acid and bile tolerance, adhesion to epithelial cells of probiotic microorganisms," *UPB Scientific Bulletin B*, vol. 72, no. 2, pp. 1454–2331, 2010.
- [63] K. Singhal, H. Joshi, and B. L. Chaudhary, "Bile and acid tolerance ability of probiotic *Lactobacillus* strains," *Journal of Global Pharma Technology*, vol. 2, no. 12, pp. 17–25, 2010.
- [64] R. P. K. Sahadeva, S. F. Leong, K. H. Chua et al., "Survival of commercial probiotic strains to pH and bile," *International Food Research Journal*, vol. 18, no. 4, pp. 1515–1522, 2011.
- [65] M. Saxelin, T. Pessi, and S. Salminen, "Fecal recovery following oral administration of *Lactobacillus* strain GG (ATCC 53103) in gelatine capsules to healthy volunteers," *International Journal of Food Microbiology*, vol. 25, no. 2, pp. 199–203, 1995.
- [66] B. R. Goldin, S. L. Gorbach, M. Saxelin, S. Barakat, L. Gualtieri, and S. Salminen, "Survival of *Lactobacillus* species (strain GG) in human gastrointestinal tract," *Digestive Diseases and Sciences*, vol. 37, no. 1, pp. 121–128, 1992.
- [67] R. M. Satokari, E. E. Vaughan, A. D. L. Akkermans, M. Saarela, and W. M. de Vos, "Polymerase chain reaction and denaturing gradient gel electrophoresis monitoring of fecal *Bifidobacterium* populations in a prebiotic and probiotic feeding trial," *Systematic and Applied Microbiology*, vol. 24, no. 2, pp. 227–231, 2001.
- [68] G. Önning, A. Berggren, M. Drevelius, B. Jeppsson, A. M. Lindberg, and M. L. Johansson Hagslätt, "Influence of a drink containing different antioxidants and *Lactobacillus plantarum* 299v on plasma total antioxidant capacity, selenium status and faecal microbial flora," *International Journal of Food Sciences and Nutrition*, vol. 54, no. 4, pp. 281–289, 2003.
- [69] F. Haschke, W. Wang, G. Ping et al., "Clinical trials prove the safety and efficacy of the probiotic strain *Bifidobacterium* Bb12 in follow-up formula and growing-up milks," *Monatsschrift für Kinderheilkunde*, vol. 146, no. 1, supplement, pp. S26–S30, 1998.
- [70] S. Mathys, U. von Ah, C. Lacroix et al., "Detection of the pediocin gene *pedA* in strains from human faeces by real-time PCR and characterization of *Pediococcus acidilactici* UVA1," *BMC Biotechnology*, vol. 7, article article 55, 2007.
- [71] S. S. Choi, B. Y. Kang, M. J. Chung et al., "Safety assessment of potential lactic acid bacteria *Bifidobacterium longum* SPM1205 isolated from healthy Koreans," *Journal of Microbiology*, vol. 43, no. 6, pp. 493–498, 2005.
- [72] M. J. Hill, "Intestinal flora and endogenous vitamin synthesis," *European Journal of Cancer Prevention*, vol. 6, no. 1, pp. S43–S45, 1997.
- [73] K. E. Scholz-Ahrens, P. Ade, B. Marten et al., "Prebiotics, probiotics, and synbiotics affect mineral absorption, bone mineral content, and bone structure," *Journal of Nutrition*, vol. 137, no. 3, pp. 838S–846S, 2007.